190 related articles for article (PubMed ID: 27440271)
1. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.
Duran R; Mirpour S; Pekurovsky V; Ganapathy-Kanniappan S; Brayton CF; Cornish TC; Gorodetski B; Reyes J; Chapiro J; Schernthaner RE; Frangakis C; Lin M; Sun JD; Hart CP; Geschwind JF
Clin Cancer Res; 2017 Jan; 23(2):536-548. PubMed ID: 27440271
[TBL] [Abstract][Full Text] [Related]
2. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
[No Abstract] [Full Text] [Related]
3. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
[TBL] [Abstract][Full Text] [Related]
4. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.
van Breugel JMM; Geschwind JF; Mirpour S; Savic LJ; Zhang X; Duran R; Lin M; Miszczuk M; Liapi E; Chapiro J
Theranostics; 2019; 9(13):3674-3686. PubMed ID: 31281506
[TBL] [Abstract][Full Text] [Related]
5. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
[TBL] [Abstract][Full Text] [Related]
9. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
[TBL] [Abstract][Full Text] [Related]
10. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
Tran NH; Foster NR; Mahipal A; Byrne T; Hubbard J; Silva A; Mody K; Alberts S; Borad MJ
Invest New Drugs; 2021 Aug; 39(4):1072-1080. PubMed ID: 33646489
[TBL] [Abstract][Full Text] [Related]
11. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Saggar JK; Tannock IF
Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
Brenner A; Zuniga R; Sun JD; Floyd J; Hart CP; Kroll S; Fichtel L; Cavazos D; Caflisch L; Gruslova A; Huang S; Liu Y; Lodi A; Tiziani S
Neuro Oncol; 2018 Aug; 20(9):1231-1239. PubMed ID: 29415215
[TBL] [Abstract][Full Text] [Related]
13. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.
Savic LJ; Schobert IT; Peters D; Walsh JJ; Laage-Gaupp FM; Hamm CA; Tritz N; Doemel LA; Lin M; Sinusas A; Schlachter T; Duncan JS; Hyder F; Coman D; Chapiro J
Clin Cancer Res; 2020 Jan; 26(2):428-438. PubMed ID: 31582517
[TBL] [Abstract][Full Text] [Related]
14. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.
Doemel LA; Santana JG; Savic LJ; Gaupp FML; Borde T; Petukhova-Greenstein A; Kucukkaya AS; Schobert IT; Hamm CA; Gebauer B; Walsh JJ; Rexha I; Hyder F; Lin M; Madoff DC; Schlachter T; Chapiro J; Coman D
Eur Radiol; 2022 Apr; 32(4):2437-2447. PubMed ID: 34718844
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
[No Abstract] [Full Text] [Related]
16. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
[TBL] [Abstract][Full Text] [Related]
17. [Transhepatic arterial embolization with superparamagnetic iron oxide and lipiodol for the treatment of VX2 tumor in rabbits].
Liang Q; Deng L; Feng Z; Liu X; Ding J; Hu P; Wang W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1248-1256. PubMed ID: 29187650
[TBL] [Abstract][Full Text] [Related]
18. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
Hegde A; Jayaprakash P; Couillault CA; Piha-Paul S; Karp D; Rodon J; Pant S; Fu S; Dumbrava EE; Yap TA; Subbiah V; Bhosale P; Coarfa C; Higgins JP; Williams ET; Wilson TF; Lim J; Meric-Bernstam F; Sumner E; Zain H; Nguyen D; Nguyen LM; Rajapakshe K; Curran MA; Hong DS
Clin Cancer Res; 2021 Jun; 27(11):3050-3060. PubMed ID: 33771853
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of curcumin liposome after transcatheter arterial embolization in VX2 rabbits.
Zhang X; Dai F; Chen J; Xie X; Xu H; Bai C; Qiao W; Shen W
Cancer Biol Ther; 2019; 20(5):642-652. PubMed ID: 30621501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
